Literature DB >> 7834186

Decrease in calcium currents induced by aminoglycoside antibiotics in frog motor nerve endings.

R S Redman1, E M Silinsky.   

Abstract

1. The effects of the aminoglycoside antibiotics, streptomycin, neomycin and gentamicin were examined on perineural currents and evoked acetylcholine (ACh) release at frog motor nerve endings. 2. In the standard solutions used previously to measure Ca2+ currents, streptomycin reduced the peak amplitude of the Ca2+ component of the perineural current. 3. In a solution in which changes in both Ca2+ currents and evoked ACh release can be recorded simultaneously, both Ca2+ currents and evoked ACh release were reduced by aminoglycosides in the potency order neomycin > streptomycin > gentamicin. This potency sequence is similar to that reported previously for these agents as inhibitors of neurally-evoked contractions of mammalian skeletal muscle. 4. These data suggest that the presynaptic inhibitory effects of aminoglycoside antibiotics at the neuromuscular junction occur as a consequence of a reduction in Ca2+ currents in the motor nerve terminal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7834186      PMCID: PMC1510120          DOI: 10.1111/j.1476-5381.1994.tb16998.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Effects of antibiotics on uptake of calcium into isolated nerve terminals.

Authors:  W D Atchison; L Adgate; C M Beaman
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

Review 2.  Antibiotic blockade of neuromuscular function.

Authors:  C Pittinger; R Adamson
Journal:  Annu Rev Pharmacol       Date:  1972       Impact factor: 13.820

3.  Mutual potentiation of the neuromuscular effects of antibiotics and relaxants.

Authors:  L Burkett; G B Bikhazi; K C Thomas; D A Rosenthal; M G Wirta; F F Foldes
Journal:  Anesth Analg       Date:  1979 Mar-Apr       Impact factor: 5.108

4.  Presynaptic currents in frog motor endings.

Authors:  A Mallart
Journal:  Pflugers Arch       Date:  1984-01       Impact factor: 3.657

5.  Mechanism of neuromuscular block by streptomycin: a voltage clamp analysis.

Authors:  J M Farley; C H Wu; T Narahashi
Journal:  J Pharmacol Exp Ther       Date:  1982-08       Impact factor: 4.030

6.  Inhibitory effect of kanamycin on evoked transmitter release. Reversal by 3,4-diaminopyridine.

Authors:  J Molgó; M Lemeignan; T Uchiyama; P Lechat
Journal:  Eur J Pharmacol       Date:  1979-07-15       Impact factor: 4.432

7.  On the calcium receptor that mediates depolarization-secretion coupling at cholinergic motor nerve terminals.

Authors:  E M Silinsky
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

8.  Neurotoxic aminoglycoside antibiotics are potent inhibitors of [125I]-Omega-Conotoxin GVIA binding to guinea-pig cerebral cortex membranes.

Authors:  H G Knaus; J Striessnig; A Koza; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

9.  ATP released together with acetylcholine as the mediator of neuromuscular depression at frog motor nerve endings.

Authors:  R S Redman; E M Silinsky
Journal:  J Physiol       Date:  1994-05-15       Impact factor: 5.182

10.  Effects of the aminoglycoside antibiotics, streptomycin and neomycin, on neuromuscular transmission. I. Presynaptic considerations.

Authors:  J F Fiekers
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

View more
  2 in total

1.  Stretch induced endothelin-1 secretion by adult rat astrocytes involves calcium influx via stretch-activated ion channels (SACs).

Authors:  Lyle W Ostrow; Thomas M Suchyna; Frederick Sachs
Journal:  Biochem Biophys Res Commun       Date:  2011-05-25       Impact factor: 3.575

2.  Calcium-sensing receptor: a high-affinity presynaptic target for aminoglycoside-induced weakness.

Authors:  Mark T Harnett; Wenyan Chen; Stephen M Smith
Journal:  Neuropharmacology       Date:  2009-07-29       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.